In This Article:
NEW YORK, NY / ACCESSWIRE / August 18, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.
Anheuser-Busch Inbev Sa/Nv (BUD)
Lawsuit on behalf of: investors who purchased March 1, 2018 - October 24, 2018
Lead Plaintiff Deadline : August 20, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/anheuser-busch-inbev-sa-nv-loss-form?prid=3033&wire=1
According to the filed complaint, Defendants issued a steady stream of materially false and misleading reassurances about Anheuser Busch’s deleveraging efforts, cost cutting measures, EBITDA growth, the sufficiency of its liquidity and its debt maturity profile during the Class Period. These positive statements by Defendants created a false impression and materially misled investors about the Company’s finances, including the sustainability of Anheuser-Busch’s dividends. Once Defendants chose to speak about Anheuser-Busch’s finances, they had a duty to speak completely and truthfully, including speaking about those factors that were then having a material adverse effect on the Company’s deleveraging efforts.
Abiomed, Inc. (ABMD)
Lawsuit on behalf of: investors who purchased January 31, 2019 - July 31, 2019
Lead Plaintiff Deadline : October 7, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abiomed-inc-loss-form?prid=3033&wire=1
According to the filed complaint, during the class period, Abiomed, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Abiomed’s revenue growth was in decline; (ii) the Company did not have a sufficient plan in place to stem its declining revenue growth; (iii) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (iv) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Granite Construction Incorporated (GVA)
Lawsuit on behalf of: investors who purchased October 26, 2018 - August 1, 2019
Lead Plaintiff Deadline : October 15, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/granite-construction-incorporated-loss-form?prid=3033&wire=1